Impact of Duration of Exposure to Intraretinal Fluid on Visual Outcomes in Neovascular Age-Related Macular Degeneration

Macular Diseases

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Br J Ophthalmol

Martin-Pinardel R, Izquierdo-Serra J, Bernal-Morales C, De Zanet S, Garay-Aramburu G, Puzo M, Arruabarrena C, Sararols L, Abraldes M, Broc L, Escobar-Barranco JJ, Figueroa M, Zapata MA, Ruiz-Moreno JM, Parrado-Carrillo A, Moll-Udina A, Alforja S, Figueras-Roca M, Gómez-Baldó L, Ciller C, Apostolopoulos S, Mishchuk A, Casaroli-Marano RP, Zarranz-Ventura J, from the FRB SPAIN-IMAGE Project Investigators

doi: 10.1136/bjo-2024-325615

Macular Diseases

Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Ophthalmology

Nanji K, Grad J, Hatamnejad A, McKechnie T, Phillips M, Cheung CMG, Patel PJ, Marco RD, Borrelli E, Steel DH, Sadda SR, Wong TY, Sivaprasad S, Guymer R, Wykoff CC, Chaudhary V

doi: 10.1016/j.ophtha.2025.06.018

Macular DiseasesRetinal Diseases

Impact of diabetes and diabetic retinopathy on neovascular exudative age-related macular degeneration

Acta Ophthalmol

Viggiano P, Santoro M, Boscia G, Porreca A, Borrelli E, Bacherini D, Lombardi L, Fumarola R, Grassi MO, Termite AC, Reibaldi M, Alessio G, Sadda S, Boscia F

doi: 10.1111/aos.17502

Macular Diseases

MERLIN: Two-Year Results of Brolucizumab in Participants With Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Ophthalmology

Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Heier JS, Khanani AM

doi: 10.1016/j.ophtha.2024.08.022

Macular DiseasesRetinal Diseases

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Ophthalmol Retina

Ting Yap DW, Jyn Tan BK, Yi Chong KT, Wong TY, Gemmy Cheung CM

doi: 10.1016/j.oret.2025.01.010

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Br J Ophthalmol

Vu TA, Fenwick EK, Man REK, Thakur S, Tan ACS, Cheung CMG, Gupta P, Lamoureux EL

doi: 10.1136/bjo-2024-325713

Macular Diseases

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

J Clin Med

Nowak M, Cybulska AM, Schneider-Matyka D, Grochans E, Walaszek I, Panczyk M, Nowicki GJ, Rachubińska K

doi: 10.3390/jcm14020447

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Related content

Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database

Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Impact of diabetes and diabetic retinopathy on neovascular exudative age-related macular degeneration

MERLIN: Two-Year Results of Brolucizumab in Participants With Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Acceptance of the Disease in Patients Diagnosed with Neovascular Age-Related Macular Degeneration Depending on Visual Parameters-Before and After a Series of Seven Intravitreal Injections

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis